Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 219, Issue 5, Pages -Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20211681
Keywords
-
Categories
Funding
- National Cancer Institute [R01 CA201312]
- Wistar Cancer Center support grant [P30 CA10815]
- National Cancer Institute of the National Institutes of Health T32 training grant [5T32CA009171]
Ask authors/readers for more resources
Exonic sequencing identified a previously unreported heterozygous mutation in POT1 p.(L2595) in a family with idiopathic pulmonary fibrosis (IPF). This mutation leads to telomere loss, DNA damage, and premature senescence in patient cells. The study reveals POT1(L259S) as a pathogenic driver of IPF and provides insights for potential gene therapy options.
Exonic sequencing identified a family with idiopathic pulmonary fibrosis (IPF) containing a previously unreported heterozygous mutation in POT1 p.(L2595). The family displays short telomeres and genetic anticipation. We found that POT1(L259S) is defective in binding the telomeric overhang, nuclear accumulation, negative regulation of telomerase, and lagging strand maintenance. Patient cells containing the mutation display telomere loss, lagging strand defects, telomere-induced DNA damage, and premature senescence with G1 arrest. Our data suggest POT1(L259S) is a pathogenic driver of IPF and provide insights into gene therapy options.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available